CLADRIBINE(2-CDA) AND CYTARABINE(ARA-C) IS AN EFFECTIVE SALVAGE REGIMEN IN REFRACTORY/RELAPSED ACUTE MYELOID LEUKAEMIA IN CHILDREN

被引：0
|
作者：
Chinnaswamy, Girish [1 ]
Prasad, Maya [1 ]
Dwivedi, Pankaj [1 ]
Patil, Vijay [1 ]
Arora, Brijesh [1 ]
Banavali, Shripad [1 ]
机构：
[1] Tata Mem Hosp, Dept Med Oncol Pediat, Mumbai 400012, Maharashtra, India
来源：
PEDIATRIC BLOOD & CANCER | 2012年 / 59卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1040 / 1040
页数：1
相关论文
共 50 条
  • [41] 2-Cda and Ara-C combined chemotherapy as a rescue for pediatric patients with refractory langerhans cell histiocytosis (LCH) and hematological dysfunction.
    Bernard, F
    Thomas, C
    Bertrand, Y
    Parker, JL
    Ouache, M
    Chastagner, P
    Perel, Y
    Vermylen, C
    Donadieu, J
    BLOOD, 2003, 102 (11) : 403A - 403A
  • [42] Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients
    Russo, D
    Malagola, M
    Vivo, A
    Fiacchini, M
    Martinelli, G
    Piccaluga, PP
    Damiani, D
    Candoni, A
    Michielutti, A
    Castelli, M
    Testoni, N
    Ottaviani, E
    Rondoni, M
    Pricolo, G
    Mazza, P
    Zuffa, E
    Zaccaria, A
    Raspadori, D
    Bocchia, M
    Lauria, F
    Bonini, A
    Avanzini, P
    Gugliotta, L
    Visani, G
    Fanin, R
    Baccarani, M
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (02) : 172 - 179
  • [43] Mylotarg, liposomal daunorubicin, Ara-C and cyclosporine (MDAC) regimen in patients with relapsed/refractory acute myelogenous leukemia (AML)
    Apostolidou, E
    Cortes, J
    Tsimberidou, AM
    Estey, E
    Kantarjian, H
    Giles, F
    BLOOD, 2002, 100 (11) : 268B - 268B
  • [44] Fludarabine and high dose cytarabine (FLA): a well tolerated salvage regimen in acute myeloid leukaemia
    Strickland, AH
    Seymour, C
    Prince, HM
    Wolf, M
    Juneja, S
    Januszewicz, EH
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1999, 29 (04): : 556 - 558
  • [45] Mylotarg, fludarabine, cytarabine (Ara-C) and cyclosporine (MFAC) combination regimen in patients with CD33-positive primary resistant or relapsed acute myeloid leukemia (AML).
    Tsimberidou, AM
    Estey, E
    Cortes, J
    Thomas, D
    Garcia-Manero, G
    Faderl, S
    Verstovesk, S
    O'Brien, S
    Kantarjian, H
    Giles, F
    BLOOD, 2002, 100 (11) : 339A - 340A
  • [46] High Activity of Cladribine (2-CdA) Combined with Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome after Azacitidine Failure
    Wisniewski, Kamil
    Madry, Krzysztof
    Grosicki, Sebastian
    Malecki, Piotr
    Pula, Bartosz
    Watek, Marzena
    Lech-Maranda, Ewa
    Tybor, Joanna Gora
    BLOOD, 2019, 134
  • [47] A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Christian, Sonia
    Patel, Pritesh
    Agrawal, Vaibhav
    Griffin, Shawn
    Cahill, Kirk
    Khan, Irum
    Sweiss, Karen
    Shergill, Ardaman
    Calip, Gregory Sampang
    Stock, Wendy
    Odenike, Olatoyosi
    Konig, Heiko
    Quigley, John G.
    BLOOD, 2018, 132
  • [48] Pilot trial of Mylotarg, Topotecan and Ara-C in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Alvarez, RH
    Estey, EH
    Kantarjian, HM
    Giles, FJ
    Beran, M
    Thomas, D
    Cortes, JE
    BLOOD, 2002, 100 (11) : 340A - 341A
  • [49] Enhancing effect of β-elemene emulsion on chemotherapy with harringtonine, aclacinomycin and Ara-c in treatment of refractory/relapsed acute myeloid leukemia
    Zheng, Cuiping
    Cai, Xiaoping
    Wu, Shenghao
    Liu, Zhen
    Shi, Yuejian
    Zhou, Wenjin
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2014, 30 (06) : 1270 - 1272
  • [50] A Phase 1 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Ara-C in Patients with Relapsed or Refractory Acute Myeloid Leukemia
    DeAngelo, Daniel J.
    Fathi, Amir T.
    Werner, Lillian
    Avigan, David
    Luptakova, Katarina
    Wadleigh, Martha
    Steensma, David P.
    Hobbs, Gabriela Soriano
    Attar, Eyal C.
    Amrein, Philip C.
    Stone, Richard M.
    Ballen, Karen K.
    BLOOD, 2015, 126 (23)
12345